Annual meeting to highlight JLR junior associate editors
The Journal of Lipid Research recently recruited four outstanding early-career scientists to serve as junior associate editors: Raymond Blind of the Vanderbilt University School of Medicine, Gissette Reyes–Soffer of the Columbia University Irving Medical Center, Brandon Davies of the University of Iowa Carver College of Medicine and Rotonya Carr of the University of Pennsylvania Perelman School of Medicine.
The JLR instituted the junior associate editors program to facilitate development of review skills and associated editorial activities. Since their appointments, these four junior AEs not only have been involved with the review process but also have organized a series of virtual issues highlighting the cutting-edge research published by the journal on lipoprotein clearance, sphingolipids and lipoprotein (a). A fourth virtual issue is due to be published this month.
When the American Society for Biochemistry and Molecular Biology Meetings Committee asked us to organize the JLR session for the upcoming annual meeting in San Diego, it seemed obvious that there was no better way to highlight the journal’s commitment to early-career scientists than to have a session centered around our junior AEs. The JLR session, titled “Lipid Diversity and Disease: Spotlight on Journal of Lipid Research Junior Associate Editors,” will highlight their lipid-based research ranging from basic to clinical studies.
As co-chairs of this JLR session, we invite you to read in the following pages about our junior AEs and the exciting work they will present on April 7 at the 2020 ASBMB Annual Meeting.
Join the ASBMB Today mailing list
Sign up to get updates on articles, interviews and events.
For small-molecule cancer drugs, context is everything. Drugs that ameliorate cancer in some tissues may increase the cancer risk in others. Researcher Stephen Safe has turned this challenge into an opportunity.
Awards, promotions, milestones and more. Find out what's going on in the lives of ASBMB members.
Wayne Fairbrother leads a department at Genentech tasked with validating disease-associated targets and determining whether they could be feasible for drug development.